Hutchmed shares slide as recalls cancer treatment Tazverik
9th Mar 2026 10:49
(Alliance News) - Hutchmed China Ltd on Monday saw its shares fall after reporting the withdrawal of a cancer medication which it licenses from Ipsen SA. Read More
| Price | 216.00p on 12-03-2026 at 12:50:10 |
|---|---|
| Change | -2.00p -0.92% |
| Buy | 216.00p |
| Sell | 210.00p |
| Last Trade: | Buy 11.00 at 216.00p |
| Day's Volume: | 5,996 |
| Last Close: | 218.00p |
| Open: | 219.00p |
| ISIN: | KYG4672N1198 |
| Day's Range | 211.00p - 219.00p |
| 52wk Range: | 187.50p - 292.00p |
| Market Capitalisation: | £1.86b |
| VWAP: | 212.49534p |
| Shares in Issue: | 859.52m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Hutchmed (HCM) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 11 | 216.00p | SI Trade |
11:03:40 - 12-Mar-26 |
| Buy* | 3 | 216.00p | Automatic Execution |
11:03:40 - 12-Mar-26 |
| Sell* | 2,800 | 210.04p | Ordinary |
10:28:29 - 12-Mar-26 |
| Sell* | 2 | 211.00p | Automatic Execution |
09:42:54 - 12-Mar-26 |
| Buy* | 1,492 | 219.00p | Automatic Execution |
09:36:53 - 12-Mar-26 |
| Sell* | 1,663 | 210.729p | Ordinary |
09:23:01 - 12-Mar-26 |
| Buy* | 748 | 218.00p | Suspected BUY Trade |
16:35:09 - 11-Mar-26 |
| Buy* | 1,640 | 219.00p | Automatic Execution |
16:23:06 - 11-Mar-26 |
| Buy* | 924 | 218.00p | Suspected BUY Trade |
16:22:21 - 11-Mar-26 |
| Buy* | 1,274 | 218.00p | Suspected BUY Trade |
16:22:20 - 11-Mar-26 |
Hutchmed (HCM) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 11th Mar 2026 8:30 am | RNS | Vesting of awards under Long Term Incentive Plan |
| 11th Mar 2026 8:30 am | RNS | Vesting of awards under Long Term Incentive Plan |
| 9th Mar 2026 9:30 am | RNS | Update on Licensed Oncology Product in China |
| 6th Mar 2026 8:30 am | RNS | Directorate change |
| 5th Mar 2026 1:00 pm | RNS-R | Publication of Form 20-F |
| 5th Mar 2026 11:00 am | RNS | 2025 Full Year Results and Business Updates |
| 4th Mar 2026 8:30 am | RNS-R | HUTCHMED Initiates Global Trial of ATTC Candidate |
| 6th Feb 2026 8:30 am | RNS | HUTCHMED to Announce 2025 Final Results |
| 14th Jan 2026 7:00 am | RNS-R | Publication of Phase III Results in The Lancet |
| 7th Jan 2026 7:00 am | RNS-R | Positive Topline Results of Phase III Trial |